世界のエファビレンツ/テノホビル/エムトリシタビン併用薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-105X05850 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、エファビレンツ/テノホビル/エムトリシタビン併用薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。エファビレンツ/テノホビル/エムトリシタビン併用薬の種類別市場規模（10錠、30錠）、用途別市場規模（病院、クリニック、ドラッグセンター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・エファビレンツ/テノホビル/エムトリシタビン併用薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Gilead Sciences、Cipla、Emcure Pharmaceuticals、Mylan Pharmaceuticals、Sun Pharmaceutical Industries、Veritaz Healthcare、Alkem Laboratories ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：10錠、30錠 ・用途別分析2016年-2026年：病院、クリニック、ドラッグセンター、その他 ・エファビレンツ/テノホビル/エムトリシタビン併用薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・エファビレンツ/テノホビル/エムトリシタビン併用薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・エファビレンツ/テノホビル/エムトリシタビン併用薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・エファビレンツ/テノホビル/エムトリシタビン併用薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・エファビレンツ/テノホビル/エムトリシタビン併用薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Efavirenz/Tenofovir/Emtricitabine Combination Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Efavirenz/Tenofovir/Emtricitabine Combination Drug size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Efavirenz/Tenofovir/Emtricitabine Combination Drug market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Efavirenz/Tenofovir/Emtricitabine Combination Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
10 Tables
30 Tables

Market segment by Application can be divided into
Hospital
Clinic
Drug Center
Other

The key market players for global Efavirenz/Tenofovir/Emtricitabine Combination Drug market are listed below:
Gilead Sciences
Cipla
Emcure Pharmaceuticals
Mylan Pharmaceuticals
Sun Pharmaceutical Industries
Veritaz Healthcare
Alkem Laboratories

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Efavirenz/Tenofovir/Emtricitabine Combination Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 10 Tables
1.2.3 30 Tables
1.3 Market Analysis by Application
1.3.1 Overview: Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size & Forecast
1.4.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Value (2016-2026))
1.4.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume (2016-2026)
1.4.3 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity Analysis
1.5.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Total Production Capacity (2016-2026)
1.5.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Drivers
1.6.2 Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Restraints
1.6.3 Efavirenz/Tenofovir/Emtricitabine Combination Drug Trends Analysis
2 Manufacturers Profiles
2.1 Gilead Sciences
2.1.1 Gilead Sciences Details
2.1.2 Gilead Sciences Major Business
2.1.3 Gilead Sciences Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.1.4 Gilead Sciences Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Cipla
2.2.1 Cipla Details
2.2.2 Cipla Major Business
2.2.3 Cipla Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.2.4 Cipla Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Emcure Pharmaceuticals
2.3.1 Emcure Pharmaceuticals Details
2.3.2 Emcure Pharmaceuticals Major Business
2.3.3 Emcure Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.3.4 Emcure Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Mylan Pharmaceuticals
2.4.1 Mylan Pharmaceuticals Details
2.4.2 Mylan Pharmaceuticals Major Business
2.4.3 Mylan Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.4.4 Mylan Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Sun Pharmaceutical Industries
2.5.1 Sun Pharmaceutical Industries Details
2.5.2 Sun Pharmaceutical Industries Major Business
2.5.3 Sun Pharmaceutical Industries Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.5.4 Sun Pharmaceutical Industries Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Veritaz Healthcare
2.6.1 Veritaz Healthcare Details
2.6.2 Veritaz Healthcare Major Business
2.6.3 Veritaz Healthcare Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.6.4 Veritaz Healthcare Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Alkem Laboratories
2.7.1 Alkem Laboratories Details
2.7.2 Alkem Laboratories Major Business
2.7.3 Alkem Laboratories Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
2.7.4 Alkem Laboratories Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Manufacturer
3.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Efavirenz/Tenofovir/Emtricitabine Combination Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Efavirenz/Tenofovir/Emtricitabine Combination Drug Manufacturer Market Share
3.4.2 Top 6 Efavirenz/Tenofovir/Emtricitabine Combination Drug Manufacturer Market Share
3.5 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Region
4.1.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2016-2026)
4.2 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026)
4.3 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026)
4.4 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026)
4.5 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026)
4.6 Middle East and Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Type (2016-2026)
5.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Type (2016-2026)
5.3 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Application (2016-2026)
6.2 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Application (2016-2026)
6.3 Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2026)
7.2 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2026)
7.3 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Country
7.3.1 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2026)
8.2 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2026)
8.3 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Country
8.3.1 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Region
9.3.1 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2026)
10.2 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2026)
10.3 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Country
10.3.1 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size by Country
11.3.1 Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Efavirenz/Tenofovir/Emtricitabine Combination Drug Typical Distributors
12.3 Efavirenz/Tenofovir/Emtricitabine Combination Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Sciences Major Business
Table 5. Gilead Sciences Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 6. Gilead Sciences Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Cipla Basic Information, Manufacturing Base and Competitors
Table 8. Cipla Major Business
Table 9. Cipla Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 10. Cipla Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Emcure Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 12. Emcure Pharmaceuticals Major Business
Table 13. Emcure Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 14. Emcure Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Mylan Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Mylan Pharmaceuticals Major Business
Table 17. Mylan Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 18. Mylan Pharmaceuticals Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Sun Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 20. Sun Pharmaceutical Industries Major Business
Table 21. Sun Pharmaceutical Industries Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 22. Sun Pharmaceutical Industries Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Veritaz Healthcare Basic Information, Manufacturing Base and Competitors
Table 24. Veritaz Healthcare Major Business
Table 25. Veritaz Healthcare Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 26. Veritaz Healthcare Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Alkem Laboratories Basic Information, Manufacturing Base and Competitors
Table 28. Alkem Laboratories Major Business
Table 29. Alkem Laboratories Efavirenz/Tenofovir/Emtricitabine Combination Drug Product and Services
Table 30. Alkem Laboratories Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 32. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Efavirenz/Tenofovir/Emtricitabine Combination Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 35. Head Office and Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Site of Key Manufacturer
Table 36. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Region (2016-2021e) & (K Pcs)
Table 37. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Region (2021-2026) & (K Pcs)
Table 38. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2016-2021e) & (USD Million)
Table 39. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2021-2026) & (USD Million)
Table 40. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 41. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 42. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Type (2016-2021e) & (USD Million)
Table 43. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Type (2021-2026) & (USD Million)
Table 44. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 45. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Type (2021-2026) & (USD/Pcs)
Table 46. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 47. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 48. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Application (2016-2021e) & (USD Million)
Table 49. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Application (2021-2026) & (USD Million)
Table 50. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 51. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Application (2021-2026) & (USD/Pcs)
Table 52. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2016-2021e) & (K Pcs)
Table 53. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2021-2026) & (K Pcs)
Table 54. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2021e) & (USD Million)
Table 55. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 56. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 57. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 58. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 59. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 60. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2016-2021e) & (K Pcs)
Table 61. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2021-2026) & (K Pcs)
Table 62. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2021e) & (USD Million)
Table 63. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 64. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 65. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 66. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 67. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 68. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Region (2016-2021e) & (K Pcs)
Table 69. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Region (2021-2026) & (K Pcs)
Table 70. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2016-2021e) & (USD Million)
Table 71. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 73. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 74. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 75. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 76. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2016-2021e) & (K Pcs)
Table 77. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2021-2026) & (K Pcs)
Table 78. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2021e) & (USD Million)
Table 79. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 80. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 81. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 82. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 83. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 84. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2016-2021e) & (K Pcs)
Table 85. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Country (2021-2026) & (K Pcs)
Table 86. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2016-2021e) & (USD Million)
Table 87. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2016-2021e) & (K Pcs)
Table 89. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Type (2021-2026) & (K Pcs)
Table 90. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2016-2021e) & (K Pcs)
Table 91. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales by Application (2021-2026) & (K Pcs)
Table 92. Direct Channel Pros & Cons
Table 93. Indirect Channel Pros & Cons
Table 94. Efavirenz/Tenofovir/Emtricitabine Combination Drug Typical Distributors
Table 95. Efavirenz/Tenofovir/Emtricitabine Combination Drug Typical Customers
List of Figures
Figure 1. Efavirenz/Tenofovir/Emtricitabine Combination Drug Picture
Figure 2. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type in 2020
Figure 3. 10 Tables
Figure 4. 30 Tables
Figure 5. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application in 2020
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Drug Center
Figure 9. Other
Figure 10. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 11. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. United States Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Canada Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Mexico Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Germany Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. France Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. United Kingdom Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Russia Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Italy Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. China Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Japan Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Korea Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. India Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Southeast Asia Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Australia Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Brazil Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Egypt Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Saudi Arabia Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. South Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Turkey Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales (2016-2026) & (K Pcs)
Figure 32. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity (2016-2026) & (K Pcs)
Figure 33. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 34. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Drivers
Figure 35. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Restraints
Figure 36. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Trends
Figure 37. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Manufacturer in 2020
Figure 38. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Manufacturer in 2020
Figure 39. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 40. Top 3 Efavirenz/Tenofovir/Emtricitabine Combination Drug Manufacturer (Revenue) Market Share in 2020
Figure 41. Top 6 Efavirenz/Tenofovir/Emtricitabine Combination Drug Manufacturer (Revenue) Market Share in 2020
Figure 42. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Region (2016-2026)
Figure 43. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Region (2016-2026)
Figure 44. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026) & (USD Million)
Figure 45. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026) & (USD Million)
Figure 46. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026) & (USD Million)
Figure 47. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026) & (USD Million)
Figure 48. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue (2016-2026) & (USD Million)
Figure 49. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type (2016-2026)
Figure 50. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Type (2016-2026)
Figure 51. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 52. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 53. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Application (2016-2026)
Figure 54. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 55. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Country (2016-2026)
Figure 56. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Country (2016-2026)
Figure 57. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type (2016-2026)
Figure 58. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 59. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Country (2016-2026)
Figure 60. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Country (2016-2026)
Figure 61. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type (2016-2026)
Figure 62. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Country (2016-2026)
Figure 68. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Country (2016-2026)
Figure 69. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type (2016-2026)
Figure 70. South America Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Revenue Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Sales Market Share by Application (2016-2026)
Figure 75. Sales Channel: Direct Channel vs Indirect Channel
Figure 76. Methodology
Figure 77. Research Process and Data Source

---